Talha Badar: Key takeaways from molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML

Talha Badar shared a post on X:

“Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Key takeaways:

Adverse risk CG, WT1, DNMT3A, FLT3ITD were associated with high rate of MRD plus by PCR and increased relapses.

In spite of high risk molecular features, MRD- overcome bad prognostic features.”

Source: Talha Badar/X

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Authors: Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D. Freeman, Amanda Gilkes, Rosemary Gale, Tanya Rapoz-D’Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian Huntly, Nigel H. Russell, and Richard Dillon.

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.